HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Stock analysts at HC Wainwright reduced their Q4 2024 earnings per share (EPS) estimates for shares of Kamada in a research report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $0.05 per share for the quarter, down from their previous forecast of $0.08. HC Wainwright currently has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Kamada's current full-year earnings is $0.26 per share. HC Wainwright also issued estimates for Kamada's FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Separately, StockNews.com downgraded Kamada from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, August 27th.

Kamada Stock Down 0.9 %

Shares of Kamada stock traded down $0.05 during mid-day trading on Friday, reaching $5.81. 29,283 shares of the stock traded hands, compared to its average volume of 29,857. The business has a 50-day moving average of $5.48 and a 200 day moving average of $5.47. The stock has a market capitalization of $333.96 million, a PE ratio of 20.75 and a beta of 1.05. Kamada has a fifty-two week low of $4.60 and a fifty-two week high of $6.53.

Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. Kamada had a net margin of 9.92% and a return on equity of 6.36%. The business had revenue of $42.47 million during the quarter, compared to analysts' expectations of $39.70 million.

Institutional Investors Weigh In On Kamada

A number of hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new position in Kamada in the third quarter valued at about $77,000. Plato Investment Management Ltd acquired a new stake in shares of Kamada during the third quarter worth about $117,000. Vanguard Group Inc. boosted its stake in shares of Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company's stock valued at $7,433,000 after purchasing an additional 100,800 shares during the period. Finally, Y.D. More Investments Ltd boosted its stake in shares of Kamada by 1,956.0% in the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company's stock valued at $3,643,000 after purchasing an additional 690,842 shares during the period. Hedge funds and other institutional investors own 20.38% of the company's stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.